Development Of LiquiSolid Systems For Pioglitazone: A Strategy To Overcome Solubility Challenges

The solubility and dissolution rate of a drug play a pivotal role in determining its therapeutic efficacy, particularly for Biopharmaceutics Classification System (BCS) Class II drugs like Pioglitazone, which exhibit low aqueous solubility and high permeability. The present study aims to enhance the dissolution behavior and oral bioavailability of Pioglitazone using liquisolid systems. Liquisolid technology offers a promising approach to improve the solubility of poorly water-soluble drugs by converting liquid medications or drug solutions into free-flowing and compressible powder mixtures. In this investigation, Pioglitazone was formulated into liquisolid compacts using non-volatile solvents, carriers, and coating materials. A systematic optimization process was employed to achieve formulations with enhanced dissolution rates while ensuring acceptable flow properties and compactibility. The prepared formulations were characterized for physicochemical properties, including flow behavior, dissolution profile, and in vitro drug release. Results suggest that the liquisolid compacts significantly improved the dissolution rate of Pioglitazone compared to conventional tablets, thus promising better oral bioavailability.